How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

849 results for

Rivastigmine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Donepezil

analysis). Secondary efficacy measures evaluated cognition, behavior, and function. The dual primary 2009 4. Donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer' Donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance and guidelines | NICE Donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 Last updated: 11 May (...) 2016 Share Save Guidance on donepezil ( Aricept ), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (CG42) and replaces NICE technology appraisal guidance on donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new that affects

2018 Trip Latest and Greatest

142. Memantine

Guideline for Deprescribing Cholinesterase Inhibitors and Memantine . Sydney: The University of Sydney; 2018. The full guideline 2018 4. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer' Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance and guidelines | NICE Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 (...) Last updated: 11 May 2016 Share Save Guidance on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (CG42) and replaces NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new

2018 Trip Latest and Greatest

143. Drugs for Alzheimer's disease: finally delisted in France!

of copies of which have been downloaded from our website english.prescrire.org (1). In May 2018, France's Minister for Health took this negative harm-benefit balance into account. She decided that, from 1 August 2018, these drugs – donepezil, galantamine, rivastigmine and memantine – would be delisted, i.e. no longer reimbursed by the national health insurance system (2,3). This measure was not unexpected. In late 2016, the French Pharmacoeconomic (Transparency) Committee had concluded that these drugs

2018 Prescrire

144. Twenty-Five Pearls from 25 years (part 1)

provide harm data including serious adverse events that are not published elsewhere. 13 Donepezil has not been demonstrat- ed to improve outcomes of impor- tance to patients and caregivers (e.g. institutionalization or disability) Drugs for Alzheimer’s Disease [Apr-Aug 2005, issue 56]. Similarly, rivastigmine, galantamine and memantine have not been studied in terms of these important outcomes. It also concludes that acetylcholinesterase inhibitors cause gastrointestinal, muscular and other adverse

2019 Therapeutics Letter

147. Appropriate prescribing of psychotropic medication for non-cognitive symptoms in people with dementia

with antipsychotics in people with Parkinson’s disease dementia and dementia with Lewy bodies 3 , rivastigmine or donepezil may be considered for non-cognitive symptoms causing severe distress when non-pharmacological interventions have proved ineffective. People with vascular dementia or frontotemporal dementia who develop non-cognitive symptoms should NOT be prescribed acetylcholinesterase inhibitors. Memantine is indicated as a cognitive enhancer in people with moderate 7 to severe Alzheimer’s disease

2019 National Clinical Guidelines (Ireland)

149. Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder

in the treatment of posttraumatic stress disorder: a randomized, double-blind study. J Res Med Sci. 2004;9(5):240-4. 45. Ardani AR, Hosseini G, Bordbar MRF, et al. Effect of rivastigmine augmentation in treatment of male patients with combat- related chronic posttraumatic stress disorder: a randomized controlled trial. J Clin Psychopharmacol. 2017 Feb;37(1):54-60. doi: 10.1097/jcp.0000000000000624. PMID: 27930500. 46. Baker DG, Diamond BI, Gillette GM, et al. A double-blind, randomized, placebo- controlled

2019 Effective Health Care Program (AHRQ)

150. Peri-operative care of people with dementia

and being in hospital. Key areas of supportconcern: 1 Knowingaboutthepersonwithdementia,forexample, making use of a ‘This is me’ or similar document (see ‘SourcesofFurtherInformation’); Table 2 Importantdruginteractionsbetweendementiamedicationanddrugsusedinanaesthesia. Half-life;hr Recommendation/effect Cholinesteraseinhibitors Galantamine 7 Discontinue a daybeforesurgery Rivastigmine 9 Discontinue a daybeforesurgery Donepezil 70 Notrecommended Memantine 60–100 Carewithketamine

2019 Association of Anaesthetists of GB and Ireland

153. Pharmacological treatment for memory disorder in multiple sclerosis

, secondary‐progressive and primary‐progressive MS, evaluating the absolute efficacy of donepezil, ginkgo biloba, memantine and rivastigmine versus placebo in improving memory performance with diverse assessment scales. Overall, clinical and methodological heterogeneities existed across these studies. Moreover, most of them had methodological limitations on non‐specific selections of targeted sample, non‐matched variables at baseline or incomplete outcome data (high attrition bias). Only the two studies (...) inconclusive. However, there is moderate‐quality evidence that donepezil 10 mg daily was not effective in improving memory in MS patients with mild memory impairment, but had a good tolerability. Adverse events such as nausea, diarrhoea and abnormal dreams were not frequent but were associated with treatment. Ginkgo biloba, memantine and rivastigmine were safe and well tolerated and no serious adverse effects were reported. Future large‐scale RCTs with higher methodological quality are needed. Plain

2018 European Academy of Neurology

154. Drugs to avoid

laxatives Moxifloxacin Bacterial infections Serious toxicity such as liver and cardiac disorders Ciprofloxacin, Ofloxacin Donepezil (Aricept), Galantamine (Reminyl), Rivastigmine (Exelon), Memantine Alzheimer’s and other dementias Minimal efficacy; disproportionate adverse effects such as severe vomiting and syncope Support from caregivers and family Alemtuzumab (Lemtrada), Natalizumab (Tysabri), Teriflunomide (Aubagio) Multiple sclerosis Disproportionate adverse effects such as infections and liver

2018 Therapeutics Letter

155. Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine

that is characterised by a progressive loss in cognition, function and behaviour [1]. Worldwide, the number of people living with dementia is increasing every year [2]. There are currently two classes of medications available to treat the symptoms of dementia: cholinesterase inhibitors (ChEIs: donepezil, rivastigmine and galantamine) and the N- methyl-D-aspartate (NMDA) receptor antagonist, memantine [3]. These medications are not disease modifying, yet they can have important benefits to people with dementia (...) and harm to the individual. Thus, the purpose of this guideline is to assist healthcare professionals (particularly prescribers) to determine when it might be suitable to trial withdrawal of these medications for an individual. These recommendations only apply to individuals already taking one of the described medications (donepezil, rivastigmine, galantamine and/or memantine). The main points of this guideline are as follows: ? A proportion of people who have used these medications for over 12 months

2018 Clinical Practice Guidelines Portal

156. Dementia in Older People

but important part in management of dementia, providing symptomatic benefit with acetyl cholinesterase inhibitors (AChEI) (donepezil, rivastigmine and 8 galantamine) and memantine, which is a N- methyl-D-aspartate partial antagonist. AChEI have shown modest symptomatic improvement in 40-50% of people in cognitive function, global outcomes and activities of daily living. 61 Evidence suggests positive benefits for non-cognitive symptoms, especially apathy, depression and anxiety and improved function compared (...) with placebo. 62 Side effects include nausea, vomiting, diarrhoea, dizziness, weight loss and bradycardia. 63 Memantine is well tolerated, with main side- effects, including constipation, dizziness and headache and has a potential role in the management of agitation in more severe disease. In Australia and New Zealand, subsidised funding for AChEIs is only available for those with Alzheimer’s Disease. Restricted criteria are available for memantine in Australia and rivastigmine in New Zealand for those

2017 Australian and New Zealand Society for Geriatric Medicine

158. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine

and behavioural disturbances in dementia: carbamazepine (ESUOM40) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 18 of 21In 2006, NICE published a guideline on dementia: supporting people with dementia and their carers in health and social care (NICE guideline CG42), which has been incorporated into a NICE pathway. NICE guidance is also available on donepezil, galantamine, rivastigmine and memantine for the treatment

2015 National Institute for Health and Clinical Excellence - Advice

159. Parkinson's disease in adults.

of dementia with Lewy bodies. 6 At the time of publication (July 2017), rivastigmine capsules are the only treatment with a UK marketing authorisation for this indication. Donepezil, galantamine and rivastigmine patches did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's for further information. 7

2017 National Guideline Clearinghouse (partial archive)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>